Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to randomization
Patients must not have clinical signs or symptoms of active tuberculosis infection
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 14 days prior to randomization
Signs or symptoms of infection within 2 weeks before initiation of study treatment
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to first day of study
GENERAL: Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1.
Signs or symptoms of clinically relevant infection within 2 weeks prior to Day 1 of Cycle 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to start of study treatment.
Signs or symptoms of infection within 2 weeks prior to first day of study treatment
Signs or symptoms of infection within 2 weeks prior to the first study treatment
Signs or symptoms of infection within 2 weeks prior to study treatment
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of active infection within 2 weeks prior to cycle 1 day 1
Signs or symptoms of infection =< 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Biliary obstructive symptoms or signs
Symptoms/signs suggestive of influenza like illness (ILI)
Signs or symptoms of infection within 2 weeks prior to Day 1 of Cycle 1
Patients who have signs or symptoms of infection within 2 weeks before initiation of study treatment
Signs or symptoms of infection as determined by the treating team within 2 weeks prior to cycle 1, day 1.
Signs or symptoms of infection =< 2 weeks prior to registration
Signs or symptoms of infection within 2 weeks prior to week 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Cohort A (asymptomatic): Subjects must be free of neurologic signs and symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroid therapy within 10 days prior to first treatment. Cohort B (symptomatic): Subjects with neurologic signs and symptoms related to metastatic brain lesions are eligible per Amendment 02. Subjects with neurologic signs and symptoms may be treated with a total daily dose of no more than 4 mg of dexamethasone that is stable or tapering for 10 days prior to first treatment. Subjects with neurologic signs and symptoms who are not being treated with steroids are eligible for Cohort B and should have no experience of seizure within 10 days prior to first treatment.
Signs or symptoms of infection within 2 weeks prior to first dosing.
Severe infections within 4 weeks or signs or symptoms of infection within 2 weeks prior to Cycle 1
Constitutional symptoms, defined as any one or more of the following disease-related symptoms or signs:
Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1
Signs/symptoms of infection, or use of antibiotics within 2 weeks of study drug
Any signs and/or symptoms of brain metastases must be stable for ? 4 weeks
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1; abnormal urinalysis does not constitute signs/symptoms of infection unless urine culture obtained at screening grows >= 100,000 colonies of bacteria; patients with an ileal conduit and a urinalysis and/or culture that are abnormal are eligible unless they have peripheral blood white blood cell (WBC) > ULN, fever, or other symptoms suggestive of a urinary tract infection
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of severe infection (sepsis) within 2 weeks prior to treatment start
Symptoms or signs of active brain metastases;
Signs or symptoms of infection within 2 weeks prior to Cycle 1 Day 1
Patients with any signs/symptoms of interstitial pneumonia
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of progressive or uncontrolled liver disease
Signs or symptoms of infection within 2 weeks prior to the first dose of study treatment
Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1
Active B symptoms
Subjects who exhibit signs of an infection at screening will be rescheduled when symptoms have resolved
Signs or symptoms of significant infection within 2 weeks prior to Day 1
No signs or symptoms of BRONJ
